A Nonionic Surfactant/Chitosan Micelle System in an Innovative Eye Drop Formulation

Pepić, Ivan; Hafner, Anita; Lovrić, Jasmina; Pirkić, Boris; Filipović-Grčić, Jelena

doi:10.1002/jps.22137

Cited by 73 publications

(36 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[112][113][114][115][116][117][118][119] In a recently published review Cholkar and Mitra have discussed in detail about methods for nanomicelle preparation and their applications in ocular drug delivery. 94 Recently, Pepic et al attempted to deliver the dexamethasone-encapsulated Pluronic/chitosan micellar system.…”

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

“…94 Recently, Pepic et al attempted to deliver the dexamethasone-encapsulated Pluronic/chitosan micellar system. 113 It was observed that addition of chitosan to the pluronic micelle system improved in vitro drug release properties. In vivo studies conducted in rabbits demonstrated nanomicellar formulation increased AUC by 2.4-fold relative to dexamethasone suspension.…”

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

“…This formulation showed significant prolongation of miotic activity with improvement in AUC by 64%. 113 The nanomicellar approach to deliver genes to anterior ocular tissues is an emerging and promising area of research. Liaw and Robinson have explored the nonionic copolymeric system (PEO-PPO-PEO) for ocular gene delivery.…”

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

See 2 more Smart Citations

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

148

107

View full text Add to dashboard Cite

Research advancements in pharmaceutical sciences have led to the development of new strategies in drug delivery to anterior segment. Designing a new delivery system that can efficiently target the diseased anterior ocular tissue, generate high drug levels, and maintain prolonged and effective concentrations with no or minimal side effects is the major focus of current research. Drug delivery by traditional method of administration via topical dosing is impeded by ocular static and dynamic barriers. Various products have been introduced into the market that prolong drug retention in the precorneal pocket and to improve bioavailability. However, there is a need of a delivery system that can provide controlled release to treat chronic ocular diseases with a reduced dosing frequency without causing any visual disturbances. This review provides an overview of anterior ocular barriers along with strategies to overcome these ocular barriers and deliver therapeutic agents to the affected anterior ocular tissue with a special emphasis on nanotechnology-based drug delivery approaches.

show abstract

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

Section: Formulation Approaches For Anterior Chamber Deliverymentioning

confidence: 99%

See 1 more Smart Citation

Novel Strategies for Anterior Segment Ocular Drug Delivery

Cholkar

Patel

Vadlapudi

et al. 2013

Journal of Ocular Pharmacology and Therapeutics

148

107

View full text Add to dashboard Cite

show abstract

“…Nonionic surfactants are widely used in pharmaceutical, cosmetic and food industries, and bio-based surfactants are generally preferred for their biocompatibility, biodegradability, and consumer acceptance [6][7][8]. Sugars are naturally hydrophilic, while fatty acids with long aliphatic chains are hydrophobic.…”

Section: Introductionmentioning

confidence: 99%

Ethylation of Di‐rhamnolipids: A Green Route to Produce Novel Sugar Fatty Acid Nonionic Surfactants

Miao

Callow

Dashtbozorg

et al. 2014

J Surfact & Detergents

View full text Add to dashboard Cite

Sugar fatty acid nonionic surfactants have attracted great attention due to their good biodegradability, biocompatibility, and bio-based characteristics. Regioselective sugar acylation is difficult to control for chemical reactions. The immiscible nature between hydrophilic sugars and hydrophobic fatty acids also negatively affects the reaction efficiency. In the present study, a group of sugar fatty acid nonionic surfactants, ethyl di-rhamnolipids, was synthesized. Di-rhamnolipids were isolated from a Pseudomonas aeruginosa fermentation broth containing a rhamnolipid mixture with about 64 % di-rhamnolipids, and then purified by silica gel chromatography. Di-rhamnolipids were successfully ethylated at 0°C for 24 h, confirmed by HPLC-MS and 1 H-NMR analyses. Preliminary emulsification test indicated that ethyl di-rhamnolipids were a potential class of useful sugar fatty acid nonionic surfactants. The synthesis process was mild, did not require regioselective sugar acylation, and offered a new way of developing novel sugar fatty acid nonionic surfactants.

show abstract

“…In the development of nanotherapeutics, nanotechnology tools are used to improve drug solubility (eg, micelles 7 and nanocrystals 8 ), to guide drugs to the desired location of action with increased precision (ie, drug targeting 9,10 ), to control the drug's release (eg, nanoparticles 11 and liposomes 12 ), and/or to enhance the transport across biological barriers (eg, micelles 13 and nanoparticles 14 ). The main goal is to improve drug bioavailability, pharmacokinetics, efficacy, and safety to promote the treatment of diseases which currently cannot be achieved with conventional dosage forms.…”

Section: Introductionmentioning

confidence: 99%

Nanotherapeutics in the EU: an overview on current state and future directions

Hafner¹,

Lovrić²,

Lakoš³

et al. 2014

IJN

108

View full text Add to dashboard Cite

The application of nanotechnology in areas of drug delivery and therapy (ie, nanotherapeutics) is envisioned to have a great impact on public health. The ability of nanotherapeutics to provide targeted drug delivery, improve drug solubility, extend drug half-life, improve a drug’s therapeutic index, and reduce a drug’s immunogenicity has resulted in the potential to revolutionize the treatment of many diseases. In this paper, we review the liposome-, nanocrystal-, virosome-, polymer therapeutic-, nanoemulsion-, and nanoparticle-based approaches to nanotherapeutics, which represent the most successful and commercialized categories within the field of nanomedicine. We discuss the regulatory pathway and initiatives endeavoring to ensure the safe and timely clinical translation of emerging nanotherapeutics and realization of health care benefits. Emerging trends are expected to confirm that this nano-concept can exert a macro-impact on patient benefits, treatment options, and the EU economy.

show abstract

A Nonionic Surfactant/Chitosan Micelle System in an Innovative Eye Drop Formulation

Cited by 73 publications

References 39 publications

Novel Strategies for Anterior Segment Ocular Drug Delivery

Novel Strategies for Anterior Segment Ocular Drug Delivery

Ethylation of Di‐rhamnolipids: A Green Route to Produce Novel Sugar Fatty Acid Nonionic Surfactants

Nanotherapeutics in the EU: an overview on current state and future directions

Contact Info

Product

Resources

About